- Home
- JOF vs NYXH Comparison
JOF vs NYXH Comparison
Compare JOF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOF
- NYXH
- Stock Information
- Founded
- JOF 1990
- NYXH 2009
- Country
- JOF Japan
- NYXH Belgium
- Employees
- JOF N/A
- NYXH N/A
- Industry
- JOF Trusts Except Educational Religious and Charitable
- NYXH Medical/Dental Instruments
- Sector
- JOF Finance
- NYXH Health Care
- Exchange
- JOF Nasdaq
- NYXH Nasdaq
- Market Cap
- JOF 217.9M
- NYXH 261.1M
- IPO Year
- JOF N/A
- NYXH 2021
- Fundamental
- Price
- JOF $7.53
- NYXH $10.85
- Analyst Decision
- JOF
- NYXH Strong Buy
- Analyst Count
- JOF 0
- NYXH 5
- Target Price
- JOF N/A
- NYXH $17.00
- AVG Volume (30 Days)
- JOF 43.9K
- NYXH 64.9K
- Earning Date
- JOF 01-01-0001
- NYXH 03-13-2025
- Dividend Yield
- JOF 3.33%
- NYXH N/A
- EPS Growth
- JOF N/A
- NYXH N/A
- EPS
- JOF N/A
- NYXH N/A
- Revenue
- JOF N/A
- NYXH $5,668,079.00
- Revenue This Year
- JOF N/A
- NYXH $22.93
- Revenue Next Year
- JOF N/A
- NYXH $411.04
- P/E Ratio
- JOF N/A
- NYXH N/A
- Revenue Growth
- JOF N/A
- NYXH 32.65
- 52 Week Low
- JOF $6.64
- NYXH $4.27
- 52 Week High
- JOF $8.04
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- JOF 40.30
- NYXH 77.88
- Support Level
- JOF $7.48
- NYXH $8.86
- Resistance Level
- JOF $7.61
- NYXH $10.08
- Average True Range (ATR)
- JOF 0.13
- NYXH 0.60
- MACD
- JOF -0.01
- NYXH 0.22
- Stochastic Oscillator
- JOF 18.75
- NYXH 84.81
About JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.